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Abstract 
Molecular radiopharmaceuticals based on bioconjugates of chelators with peptides and proteins have 
had significant clinical impact in diagnosis and treatment of several types of cancers. In the 1990s, 
indium-111 and yttrium-90 labelled chelator-peptide/protein conjugates established the clinical utility 
of these radiopharmaceuticals for receptor-targeted g-scintigraphy imaging and systemic 
radiotherapy. Second generation bioconjugates based on peptides targeting the somatostatin II 
receptor and the prostate specific membrane antigen are now widely used for management of 
neuroendocrine and prostate cancer respectively. These bioconjugates are typically radiolabelled with 
gallium-68 for imaging of target receptor expression with Positron Emission Tomography, and the 
b--emitter, lutetium-177 for targeted radiotherapy. Innovations in radioisotope technology and 
biomolecular therapies are likely to drive the future clinical development of radiopharmaceuticals 
based on radiometals. New chelator-peptide and chelator-protein bioconjugates will underpin nuclear 
medicine advances in molecular imaging and radiotherapy. 
Introduction 
Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), 
allow quantitative whole-body molecular imaging of cancer. One class of PET and SPECT/g-
scintigraphy molecular radiopharmaceuticals incorporates a radioactive metal bound via a chelator 
attached to a peptide or protein, which targets cell-surface receptors of diseased cells. Systemic 
Peptide Receptor Radionuclide Therapy (PRRT) of cancer incorporates b-- or a-emitting radiometals 
into the same molecular architectures to deliver targeted therapeutic radiation. 
Early clinical innovations based on radiolabelled indium-111 (111In, half-life = 67 h, g 100%) for SPECT/g-
scintigraphy and b--emitting yttrium-90 (90Y, half-life = 64 h, b− 100%) for systemic radiotherapy 
established the utility of these types of diagnostic and therapeutic nuclear medicine. More recently, 
gallium-68 (68Ga, half-life = 68 min, b+ 90%, Emax = 1880 keV) PET agents and lutetium-177 (177Lu, half-
life = 6.65 days, b− 100%, g 14%) b--emitting PRRTs have made a huge impact in prostate and 
neuroendocrine cancer treatment. 
Chelators have been essential in advancing the use of radiometallated peptide and protein 
bioconjugates in clinical nuclear medicine. Here we highlight the clinical importance of bioconjugates 
of chelators with peptides and proteins in diagnostic PET/SPECT/g-scintigraphy imaging and systemic 
receptor-targeted radiotherapy. For more detailed reviews on chelator development or innovations 
in site-specific chelator conjugation chemistry, we direct readers to recent reviews.1–3 In this review, 
we adopt radiopharmaceutical nomenclature, in which square brackets denote the radioisotopic label 
of a compound.4 For example, “[111In]In-DTPA-octreotide” indicates that the In-DTPA-octreotide 
bioconjugate has been enriched or labelled with radioactive indium-111, and “fac-
[99mTc][Tc(CO)3(OH2)3]+” indicates that the [Tc(CO)3(OH2)3]+ complex has been enriched or labelled with 
radioactive technetium-99m. 
1990s: Radiolabelled peptides and proteins are approved for clinical use 
111In-labelled bioconjugates have played a seminal role in the development of protein- and peptide-
based radiopharmaceuticals. One of the first chelators used for incorporating indium-111 into 
proteins and peptides was DTPA (diethylenetriaminepentaacetic acid, Chart 1), with prominent 
examples including: 
1. the first FDA-approved (1992) radiolabelled antibody, “OncoScint”, which uses a DTPA 
derivative to incorporate  g-emitting indium-111 into an antibody targeting a tumor-
associated glycoprotein expressed in colorectal and ovarian cancers.5 The 67 h half-life of 
indium-111 is well suited to studying the biodistribution of antibodies, which typically require 
several days to clear circulation and localise at target receptors. 
2. a prostate-specific membrane antigen (PSMA) targeting antibody, “ProstaScint” (granted FDA 
approval in 1996) used for prostate cancer imaging, similarly incorporating indium-111 into 
an antibody via an appended DTPA chelator.6 Although ProstaScint has shown limited 
predictive value and specificity as a clinical prostate cancer diagnostic, it has been 
fundamental in the development of radionuclide molecular imaging and radiotherapy of its 
target, PSMA. Notably, DTPA is incorporated site-specifically into OncoScinct and ProstaScint, 
using a GYK-DTPA peptide conjugate (Chart 1).7 Antibody glycol groups of terminal hexose 
units are oxidised, providing aldehyde motifs, which are then reacted with the primary amine 
of GYK-DTPA to furnish an imine conjugate.  
3. the [111In]InDTPA-octreotide peptide conjugate, “Octreoscan” (granted FDA approval in 1994, 
Chart 2). Octreotide and its second-generation derivative, octreotate, target the somatostatin 
II receptor (SSTR2).8 In combination with g-scintigraphy or SPECT, Octreoscan has been used 
to diagnose and localise neuroendocrine tumors that express SSTR2 (Figure 1a). Although 
incidence of neuroendocrine cancer is relatively low compared to other cancers, SSTR2-
targetted radiopharmaceuticals have significantly impacted clinical management of this 
disease. 
Radiolabelling reactions of DTPA and its conjugates with indium-111, yttrium-90 and lutetium-177, 
proceed relatively rapidly at ambient temperature,9 however, the in vivo stability of the resulting 
complexes is modest, with some dissociation of the radiometal from chelator-biomolecule 
conjugates.10 As a result, DTPA has largely been superseded by chelators such as modified DTPA 
derivatives or DOTA that demonstrate lower release of the radiometal in vivo. Incorporating a methyl 
group into the ethylene backbone of DTPA sterically hinders the release of a radiometal from the 
chelator.11,12 The first FDA-approved (2002) radiotherapeutic immunoconjugate, Zevalin, used a DTPA 
derivative, “tiuxetan”, containing a methyl group and a pendant phenyl isothiocyanate (to enable 
bioconjugation via antibody lysine residues) to incorporate the b--emitting radiotherapeutic metal ion, 
yttrium-90, into a monoclonal ibritumomab antibody targeting CD20 receptors for radionuclide 
therapy of non-Hodgkin’s lymphoma.13 
  
Chart 1. Chelators commonly used for labelling peptides and proteins with radiometals 
 
 
Chart 2. Chelator-peptide bioconjugates 
Current state-of-the-art: chelator-peptide conjugates for receptor-targeted PET imaging and 
systemic radiotherapy 
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelator, with four tertiary amine 
and four carboxylate ligands, has had enormous clinical utility in nuclear medicine. DOTA’s first 
appearance in the nuclear medicine field was in 1990 when it was found to form stable complexes 
with yttrium-90.14 It can coordinate a range of radiometallic isotopes, from the relatively small Ga3+ 
ion in a hexadentate N4O2 octahedral environment, up to lanthanide and actinide ions with large 
coordination spheres that adopt a range of complex geometries (sometimes including coordination of 
solvent molecules). The macrocyclic nature of DOTA means that it forms more thermodynamically 
stable and kinetically inert complexes than commonly used acyclic chelators such as DTPA. The rigid, 
preorganised binding site leads to a lower entropic cost of complexation, and in vivo, DOTA-based 
metal complexes exhibit higher kinetic stability and resist radiometal dissociation to a greater degree 
































































































































































































































As a result of this versatility, a single DOTA bioconjugate can be used for multiple applications. This 
has enabled the clinical development of diagnostic and therapeutic pairs, sometimes termed 
“theranostics”, in which the imaging agent is used to stage, prognose and monitor disease, and the 
targeted therapeutic is used to deliver a cytotoxic payload. To date, no single example better 
exemplifies the clinical utility of DOTA than that of its conjugates with SSTR2-targeting peptides, 
octreotide and its second-generation derivative, octreotate (Chart 2). 
The short half-life of b+-emitting gallium-68 makes it suitable for PET imaging with peptides, which 
accumulate at target tissue and clear circulation relatively quickly (within 30 min – 1 hour). Approval 
of a GMP-compliant benchtop 68Ge/68Ga-generator has driven PET imaging based on 68Ga-labelled 
peptides. Clinical studies have shown the superior diagnostic properties of [68Ga]Ga-DOTA-octreotate 
over [111In]In-DPTA-octreotide: in combination with PET, [68Ga]Ga-DOTA-octreotate has better 
sensitivity and resolution and can detect more SSTR2-expressing tumor lesions than Octreoscan 
(Figure 1b),16 and the FDA approved the diagnostic use of [68Ga]Ga-DOTA-octreotate in 2016. 
 
Figure 1: Head-to-head comparison of [111In]In-DPTA-octreotide scintigraphy (A) and [68Ga]Ga-DOTA-octreotate 
PET/CT (B) a in patient with metastatic low-grade neuroendocrine tumors. In liver, retroperitoneal and thoracic 
lymph nodes, and bones, [68Ga]Ga-DOTA-octreotate PET/CT shows multiple metastases, many of which are 
undetectable on [111In]In-DTPA-octreotide scintigraphy. This research was originally published in Journal of 
Nuclear Medicine,17 by Christophe M. Deroose et al., 2016;57:1949-1956. © SNMMI. 
 
The advent of receptor-targeted radionuclide therapy with somatostatin analogues has changed 
clinical management and treatment of neuroendocrine cancer. Both DOTA-octreotide and DOTA-
octreotate labelled with b--emitting yttrium-90 have demonstrated efficacy in systemic radiotherapy 
of metastatic neuroendocrine tumors,18,19 however, these 90Y-labelled peptides have been superseded 
in many centres by [177Lu]Lu-DOTA-octreotate. [177Lu]Lu-DOTA-octreotate, known as “Lutathera”, is 
the first peptide-based receptor targeted radionuclide therapy to be approved by the FDA. A recent 
phase III randomised clinical trial of Lutathera in patients with neuroendocrine tumors has 
demonstrated Lutathera’s therapeutic efficacy: overall, patients receiving Lutathera experienced 
longer progression free survival (65.2% of patients at month 20), compared to patients in the control 
group (10.8% at month 20) who received therapeutic doses of non-radioactive octreotide peptide.20 
The success of peptide molecular imaging and systemic radiotherapy with radiolabelled somatostatin 
analogues, coupled with the demonstrable clinical utility of radiolabelled PSMA-targeted 
immunoconjugates such as ProstaScinct, has led to peptide-based molecular imaging and systemic 
radiotherapy for prostate cancer using radiolabelled conjugates of a short, urea-containing dipeptide 
(referred to here as “PSMAt”) that targets the prostate specific membrane antigen. Imaging 
radioisotopes, including gallium-68, and radiotherapeutic isotopes, most notably lutetium-177, have 
been incorporated into PSMAt peptide conjugates via several chelators. For gallium-68 clinical PET 
imaging, this includes DOTA,21–23 a derivative of an acyclic HBED (N,N'-Bis(2-
hydroxybenzyl)ethylenediamine-N,N'-diacetic acid) chelator bearing pendant carboxylate groups24,25 
and a THP (tris(hydroxypyridinone))  chelator (Charts 1 and 2).26,27 For larger radiometals such as 
lutetium-177, DOTA chelator has again been employed. These PSMA-targeted DOTA conjugates have 
incorporated  lipophilic “linker” groups between the chelating motif and the PSMAt peptide,21–23 
resulting in favourable hydrophobic interactions between the radiotracer and a known hydrophobic 
binding “pocket” of the PSMA receptor. 
Of these chelator-PSMA conjugates, 68Ga-labelled HBED-PSMAt (known as PSMA-11) and 177Lu-
labelled DOTA-PSMAt (known as PSMA-61722) have been the most prevalently used 
radiopharmaceuticals for PET imaging and systemic radiotherapy of prostate cancer, respectively. 
[68Ga]Ga-HBED-PSMA can identify very small prostate cancer lesions and has had extraordinarily high 
impact in clinics where it is available.25 In the case of primary prostate cancer, PET imaging with 
[68Ga]Ga-HBED-PSMA can stage disease and localise metastases; in the case of recurrent prostate 
cancer, it can localise metastases early, enabling better clinical interventions. 
In 177Lu-labelled DOTA-PSMAt treatments, gallium-68 PET imaging (with [68Ga]Ga-HBED-PSMAt) is 
used (i) to determine whether or not a patient’s tumors express PSMA, and (ii) to monitor treatment 
response. g-scintigraphy imaging using g photons arising from lutetium-177 decay are also used to 
monitor accumulation and biodistribution of [177Lu]Lu-DOTA-PSMAt over cycles of therapy (Figure 2). 
Small clinical studies have demonstrated the benefits and efficacy of [177Lu]Lu-DOTA-PSMAt for 
treatment of metastatic prostate cancer,28–30 and currently, a multicentre, phase 3 randomised clinical 
trial (Vision trial, NCT03511664) of [177Lu]Lu-DOTA-PSMAt has just completed recruiting patients with 
metastatic prostate cancer. If this trial further evidences the success of [177Lu]Lu-DOTA-PSMAt 
observed in single centre clinical studies/trials, it will establish [177Lu]Lu-DOTA-PSMAt as a viable 
treatment for prostate cancer patients who previously would have had few therapeutic options left. 
 
Figure 2: A 76 year old patient after external-beam radiation therapy to bone metastases and hormone therapy. 
(A) [68Ga]Ga-HBED-PSMAt PET/CT revealed progressive bone and lymph node metastases. (B) Lutetium-177 
scintigraphy demonstrated resolution of metastases after first (1), second (2), and third (3) cycles of [177Lu]Lu-
DOTA-PSMAt radiotherapy. (C) [68Ga]Ga-HBED-PSMAt PET/CT showed excellent molecular response with 
disappearance of most PSMA-avid metastases after three cycles of [177Lu]Lu-DOTA-PSMAt radiotherapy. This 
research was originally published in Journal of Nuclear Medicine,30 by Richard P. Baum et al., 2016;57:1006-1013 
© SNMMI. 
 
Targeted radiotherapy with 225Ac-labelled bioconjugates is also an exceptionally promising field of 
experimental nuclear medicine. Recently, the first clinical studies using the alpha-emitter, actinium-
225 (half-life = 10 days, 4 a-particles per actinium-225 atom decay), with DOTA-PSMAt (PSMA-617) 
have been reported. In the first-in-man study of [225Ac]Ac-DOTA-PSMAt, two patients with advanced 
metastatic prostate cancer, who had previously undergone extensive pre-therapy, experienced 
complete response (by PET imaging with [68Ga]Ga-HBED-PSMAt).31 A second study has observed 
similarly high efficacy of [225Ac]Ac-DOTA-PSMAt in chemotherapy-naïve patients.32 
Chelator technologies to meet new clinical challenges and increase the utility, usability and 
availability of radiolabelled peptides and proteins 
Challenges in radiolabelling 
Whilst widely used, DOTA-based radiotracers have potential limitations for use as 
radiopharmaceutical agents due to their slow radiolabelling kinetics and high activation energies of 
complexation. To overcome this, heating up to 95°C is often required,33 conditions that rule out the 
use of heat-sensitive bioconjugates such as antibodies. In the case of DOTA-based 
radiopharmaceuticals with short-lived radioisotopes – for example, 68Ga-labelled peptides, which are 
typically prepared onsite at hospitals – the complexity of some of these radiolabelling procedures, 
which involve undesirable and prolonged heating, purification and handling,34 limits the widespread 
availability of such radiopharmaceuticals.   
Advances in chelator chemistry have focused on addressing such issues. Radiolabelled conjugates of 
DOTA with antibodies have been prepared by first radiolabelling a DOTA chelator derivative with a 
radiometallic ion, and then conjugating the radiolabelled DOTA derivative with an antibody.14,35 For 
example, a pre-labelled [225Ac]Ac-DOTA-tetrazine derivative has been reacted with a pancreatic 
cancer-targeting 5B1-antibody containing trans-cyclooctene (TCO) groups, via a bioorthogonal inverse 
electron demand Diels-Alder reaction.35 The resulting [225Ac]Ac-DOTA-5B1 antibody shows high 
receptor-mediated uptake in pancreatic cancers in a mouse model. Importantly, the radiochemical 
yields for this process are 35 - 45%, higher than that obtained for typical actinium-225 radiolabelling 
reactions of DOTA-antibody conjugates (typically ~10%). 
New chelators that enable fast, stable and quantitative radiometal complexation at near neutral pH, 
room temperature and low concentrations of chelator-bioconjugate can circumvent complicated 
radiolabelling protocols that involve prolonged heating and purification procedures. Many chelators 
have been developed that fulfil these criteria for a range of metal ions, from small, short-lived gallium-
68 to large, long-lived actinium-225.36–39 These chelators can enable production of 
radiopharmaceuticals using “kits”, in which the chelator-bioconjugate, buffer components and 
stabilisers are incorporated into a lyophilised vial.26,36 The radiotracer is simply formulated by addition 
of a solution containing the radioactive isotope into the kit. 
The hexadentate O6 tris(3-hydroxypyridin-4-one) (THP, Chart 1) chelator, developed for gallium-68, is 
a good example of such a chelator. A variety of THP-peptide conjugates can be quantitatively 
radiolabelled with generator-produced gallium-68 at ambient temperature, in under two minutes at 
nanomole amounts of conjugate.26,37,40,41 This chemistry has underpinned development of the 68Ga-
labelled radiopharmaceutical [68Ga]Ga-THP-PSMAt (known as “Galliprost”) that targets PSMA and is 
prepared using a one-step kit at room temperature.26 In a first-in-man trial, [68Ga]Ga-THP-PSMAt could 
identify primary and metastatic prostate tumors in PET scans, with lower uptake in off-target tissue 
than [68Ga]Ga-HBED-PSMAt.27 
Challenges in availability of radiometallic isotopes and imaging infrastructure 
Although 68Ga-radiopharmaceuticals are routinely available in many hospitals and PET clinics, a recent 
shortfall in supply of GMP-compliant 68Ge/68Ga-generators (relative to demand) has led to several 
centres being unable to supply [68Ga]Ga-DOTA-octreotate (“Netspot”) for neuroendocrine patient PET 
scans.42 It is likely that 68Ga-radiotracers for PSMA imaging will increase the demand for 68Ga-
generators. Whilst alternative methods of gallium-68 production (i.e. cyclotron production) and PET 
radionuclides (i.e. 18F-labelled PSMA-targeted radiopharmaceuticals43) could potentially alleviate this 
shortage of radiotracers, new technetium-99m based radiopharmaceuticals have emerged that could 
also meet these clinical demands. 
“Traditional” technetium-99m radiopharmaceuticals have been used in perfusion/functional imaging 
since the 1960s. Technetium-99m (half-life = 6.02 hours, g 141 keV, 90%) is available from a 
99Mo/99mTc-generator, and technetium-99m remains the most widely available radionuclide for 
nuclear medicine. It is also worth noting that g-scintigraphy and SPECT cameras are generally more 
readily accessible than PET facilities. For example, survey data collected in 2015 and 2016 across 
Europe (excluding the UK) indicated that there were 3408 g-scintigraphy/SPECT cameras and 849 PET 
scanners.44 
Many 99mTc-labelled peptide- and protein-based radiotracers have been developed over the last few 
decades. Clinical development of 99mTc-labelled peptides and proteins in the 1990s and 2000s utilised 
HYNIC (6-hydrazinopyridine-3-carboxylic acid, Chart 1) derivatives.45 In these radiopharmaceuticals, 
the HYNIC carboxylic acid group is used as an attachment point for targeting biomolecules and the 6-
hydrazinopyridine group coordinates to [99mTc]TcV in the presence of co-ligands such as EDDA 
(ethylenediamine-N,N’-diacetic acid), tricine or TPPTS (3,3ʹ,3ʺ-phosphanetriyltris(benzenesulfonic 
acid)). The coordination environment of these technetium-99m conjugates remains undefined: HYNIC 
can potentially bind to [99mTc]TcV in either a monodentate fashion through the hydrazine nitrogen 
only, or in a bidentate fashion where the pyridine nitrogen is also coordinated.46,47 It is possible that 
mixtures of such species form during 99mTc-radiolabelling. Despite this, several [99mTc]Tc-HYNIC-
peptides have been evaluated in the clinic. For example, [99mTc]Tc-EDDA/HYNIC-octreotide 
(“Tektrotyd”, Chart 3) is an alternative SSTR2-targeted agent for imaging neuroendocrine cancer 
patients.48 It is conveniently prepared from an aqueous solution of generator-produced [99mTc]TcO4- 
and a commercial two vial kit, containing HYNIC-octreotide conjugate, EDDA, tin chloride reducing 
agent, buffers and stabilisers. More recently, [99mTc]Tc-3PRGD2 has shown promising diagnostic utility 
for lung, esophageal and breast cancer and rheumatoid arthritis.49,50 In [99mTc]Tc-3PRGD2, a HYNIC 
conjugate, tricine and the TPPTS water-soluble phosphine all coordinate to the Tc metal center, and 
the HYNIC conjugate contains two copies of a cyclic RGD peptide that targets avb3-integrin receptors 
expressed in neovasculature, inflammation events and many cancers. [99mTc]Tc-3PRGD2 can be 
obtained in over 95% radiochemical yield, by adding an aqueous solution of [99mTc]TcO4- to a single kit 




Chart 3. Chelator-peptide bioconjugates for 99mTc-radiolabelling 
Although several 99mTc-labelled peptides/proteins have undergone clinical evaluation and even been 
commercialised, none have entered routine or widespread clinical use. However, recent innovations 
in 99mTc-labelled PSMA-targeted agents could potentially reverse this trend. Two classes of such 
radiopharmaceuticals have been developed. The first class consists of a PSMAt peptide conjugate 
appended to a tridentate N3 chelator consisting of a tertiary amine and two imidazole groups (MIP-
1404 and MIP-1427), which can be radiolabelled in high radiochemical yield when reacted with the 

















































































































procedures, two “kits” are required  - the first to generate the fac-[99mTc][Tc(CO)3(OH2)3]+ complex 
from generator-produced [99mTc]TcO4-, and the second to radiolabel the MIP conjugate.52 The resulting 
radiotracers, [99mTc][Tc(CO)3(MIP-1404)]+ and [99mTc][Tc(CO)3(MIP-1427)]+, have been used for both 
staging prostate cancer and assessing patients’ response to prostate cancer treatment,53–56 and 
[99mTc][Tc(CO)3(MIP-1404)]+ has recently completed phase 3 clinical trials. The second radiotracer, 
[99mTc]TcO(MAs3-PSMAt) (known as [99mTc]Tc-PSMA-I&S), consists of a 99mTc-labelled peptide 
sequence, mercaptoacetyl-D-Ser-D-Ser-D-Ser, appended to the PSMAt pharmacophore.57 Three D-
serine residues are used to increase the radiotracer’s metabolic stability. Unlike the [99mTc]Tc-MIP-
based radiotracers, this radiopharmaceutical can be formulated from a single kit (containing a tin 
chloride reducing agent, a weak chelator tartrate to stabilise reduced intermediate [99mTc]TcV species, 
buffer components and the chelator conjugate itself) in near-quantitative radiochemical yield. This 
radiotracer has entered the clinic: as well as demonstrating utility for SPECT imaging of prostate 
cancer, it has also been used in radioguided surgery.58 One day prior to surgery, prostate cancer 
patients were administered [99mTc]Tc-PSMA-I&S. During surgery, a gamma probe was used to facilitate 
localising metastases. These early studies demonstrate the successful “repurposing” of imaging agents 
as tracer agents for sensitive detection of disease in intraoperative surgery. 
Challenges in antibody-based immunotherapies: understanding heterogeneity of disease 
Monoclonal IgG antibody therapies have been transformative in the treatment of many cancers and 
autoimmune diseases. However, many patients treated with antibodies exhibit poor or 
heterogeneous responses. In some instances, this is likely due to heterogeneous expression of an 
antibody’s target receptor or heterogeneous antibody uptake at disease sites,59,60 which cannot be 
predicted or mapped from typical immunohistochemical analysis of single biopsies. The ability to 
quantitatively image antibody biodistribution at the whole-body level with PET imaging can help 
predict individual patient response, as well as aid in understanding treatment outcomes during clinical 
development. b+-emitting zirconium-89 (b+ 23%, Emax = 897 keV ) has a half-life of 78 h, and like indium-
111, this prolonged half-life is well suited for PET imaging of IgG antibodies. The increased availability 
of zirconium-89 (from cyclotrons) over the past decade has led to clinical development of highly 
sensitive zirconium-89 IgG PET imaging. 
Clinical imaging with 89Zr-labelled antibodies has used the siderophore, desferrioxamine-B (DFO, Chart 
1), a natural product, produced and released by bacteria to sequester Fe3+ from the surrounding 
environment. DFO is a hexadentate O6 chelator with three hydroxamate groups and is well suited for 
coordination of the very hard and oxiphilic Zr4+ metal ion. In radiotracers and radiopharmaceuticals, 
DFO is derivatised at the primary amine with a reactive group that enables its covalent attachment to 
biomolecules. Whilst DFO derivatives have been developed that enable site-specific modification of 
IgG antibodies,61 the majority of recent studies have utilised DFO conjugates formed from reaction of 
a DFO-isothiocyanate derivative with primary amine groups of lysine amino acid side chains, to 
provide thiourea conjugates.62 These conjugates can be radiolabelled with aqueous solutions of 
zirconium-89 at room temperature and near-neutral pH, within 1 – 2 hours.62 In vivo, zirconium-89 
remains bound to DFO and enables PET imaging of target tissue.  
89Zr-antibody imaging has been used to understand heterogeneous and variable responses to 
antibody-based cancer immunotherapies targeting immune checkpoint proteins, which allow tumors 
to evade the immune system. Atezolizumab targets the immune checkpoint PD-L1 receptor, and 
whilst atezolizumab is very effective in a sub-set of patients, many patients fail to respond to it. 
Recently, [89Zr]Zr-DFO-atezolizumab has been administered to patients with bladder cancer, triple-
negative breast cancer and non-small cell lung cancer, prior to the patients receiving a therapeutic 
dose of atezolizumab.59 [89Zr]Zr-DFO-atezolizumab PET scanning revealed significant inter-tumoral 
and intra-tumoral heterogeneity of [89Zr]Zr-DFO-atezolizumab uptake (Figure 3). Importantly, [89Zr]Zr-
DFO-atezolizumab uptake corresponded to tumor response to atezolizumab therapy, and compared 
to immunohistochemistry of biopsies, PET imaging with [89Zr]Zr-DFO-atezolisumab was significantly 
better at assessing whether patients would respond to antibody therapy. 
 
Figure 3: PET/CT images of lesions of three patients with heterogeneous intralesional [89Zr]Zr-DFO-
atezolizumab uptake on day 7 post-injection. Mediastinal lesion of a non-small cell lung cancer patient (left), 
an abdominal wall metastases of a bladder cancer patient (middle), and a bone metastasis of a triple-negative 
breast cancer patient (right). This research was originally published in Nature Medicine,59 by Frederike Bensch 
et al., 2018;24:1852-1858 © SpringerNature. 
 
Concluding remarks 
Many new receptor-targeted biomolecular therapies are being developed, particularly in the field of 
oncology, and continuing research efforts will generate more. Ongoing molecular biology research will 
also lead to a better understanding of relationships between cell surface expression of particular 
receptors and disease progression. Finally, advances in radioisotope technology and nuclear physics 
will result in radiometallic isotopes with utility in PET/SPECT diagnostic imaging or radiotherapy. 
Clinical nuclear medicine will be able to integrate these advances to provide improved diagnostic 
imaging and therapeutic agents, provided that suitable and easy-to-use chelator derivatives exist. 
Such chelators and chelator-bioconjugates will be critical for the continued development, evaluation 
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